Gareth Soloway's technical market breakdown: S&P 500 trend-line test, semiconductor unwind, AI-to-biotech rotation, USD/JPY ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

The real drug development delay? Bad communication.

Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...

HudsonAlpha Institute's HOPE-AD study offers Alzheimer's risk assessment, revealing proactive steps high-risk individuals can ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.